MultiCorp International Inc (MCIC)

[caltrader]

For the Melafind skin cancer screening device:

For all subgroups analyzed, the sensitivity of MelaFind was greater than 95%


For the Bioharp:

The total results were 629 hits out of 656 measurements (95.9%) in the experiment period, in which normal, healthy mice were not diagnosed with cancer. It can be appreciated that the diagnostic device of the invention has excellent sensitivity to biological electro-magnetic signals caused by cancer.

Now we can also detect other cancers, diabetes and many other diseases with inflammations.

Hmmmmmmm

Market Cap: Melafind $250 million (MELA)
: Bioharp $47 Million (XMDC)

Someone seems undervalued here.